GlobeNewswire

Progress and Potential for Achieving Cleaner Air on a Global Basis

Dela

Adoption of New Generation Diesel Technology Delivers Rapid Clean Air Benefits 

New understanding of global air quality highlights the need for technologies like new-generation diesel engines, which are capable of accelerating emissions reductions

WASHINGTON, April 19, 2018 (GLOBE NEWSWIRE) -- Recent reports highlighting air quality conditions in the United States (State of the Air) and globally (State of Global Air 2018) celebrate the progress made in developed and developing countries, but also emphasize significant disparities in progress toward reducing levels of key pollutants such as particulate matter and ozone.

"Achieving continued clean air progress while also sustaining economic growth is possible. Cities and countries must move to proven cleaner engines and fuels," said Allen Schaeffer, executive director of the Diesel Technology Forum. "We can and should bring the tremendous benefits of new technology diesel engines to communities and countries large and small around the world so they too can reduce emissions while efficiently building their economies and infrastructure, improving the quality of life for people everywhere."

"While it is surprising the extent that particulate matter from household cooking and non-transportation sources contributes to the health burden in the new report, the opportunities for reducing fine particle emissions from the motor vehicle and industrial engine segments are also part of the solution," said Schaeffer. "Worldwide harmonization of fuel quality and vehicle engine emissions standards would leverage the societal benefits of new diesel technology to more users around the world."

For example: Today, nearly one in every two trucks on the road in the United States are equipped with fine particle- and smog-reducing advanced clean diesel technology. In the most comprehensive study conducted on these engines, The Health Effects Institute found "substantial emissions and health benefits from US 2007/2010 and Euro VI/6 engines," demonstrating "dramatic improvements in emissions and the absence of any significant health effects."

In 2000, the U.S. Environmental Protection Agency (EPA) challenged diesel engine and truck manufacturers to achieve near-zero emissions in their products by 2010, with diesel off-road equipment manufacturers targeting 2014. Following a switch to ultra-low-sulfur diesel fuel in 2006, today's industry has not only met the near-zero challenge, but is well into the second and third generations of new diesel technologies. The industry continues to build on this success by seeking lower greenhouse gas emissions and greater fuel efficiency for the diesel engine.

The societal benefits of these efforts are now clear: According to the American Lung Association's analysis, ".the best progress [in 2018] came in the continued reduction of year-round particle pollution, thanks to cleaner power plants and increased use of cleaner vehicles and engines."

"Clean diesel technology plays an increasing role in helping cities, states and countries achieve cleaner air quality worldwide," said Schaeffer. "The latest generation diesel engines - ones that use selective catalytic reduction systems and diesel particulate filters - offer near-zero particulate matter (PM) and nitrogen oxides (NOx) emissions. With such technology, NOx emissions can be reduced by up to 90 percent while simultaneously reducing hydrocarbon and carbon monoxide emissions by 50-90 percent, and PM emissions by 30-50 percent. Ultra-low-sulfur diesel fuel immediately cuts soot emissions from diesel vehicles and equipment by 10 percent."

The State of Global Air 2018, compiled by The Health Effects Institute, the Institute for Health Metrics and Evaluation at the University of Washington, and the University of British Columbia, dramatically expands our understanding of all the sources that contribute to fine-particle air pollution; this was identified as the greatest environmental risk factor worldwide. Ninety-five percent of the world's population lives in areas exceeding the World Health Organization's (WHO) guideline for healthy air, and nearly 60 percent live in areas that do not meet even the WHO's least-stringent air quality target.

"Global considerations of air quality improvement must go beyond the road transport sector because diesel engines not only power the majority of commercial vehicles, but also nearly all marine and rail, industrial, agricultural and construction machines and equipment," said Schaeffer. "Similar clean diesel technologies that reduce fine particle emissions from commercial vehicles are now available in these large engine applications."

About The Diesel Technology Forum
The Diesel Technology Forum is a non-profit organization dedicated to raising awareness about the importance of diesel engines, fuel and technology. Forum members are leaders in clean diesel technology and represent the three key elements of the modern clean-diesel system: advanced engines, vehicles and equipment, cleaner diesel fuel and emissions-control systems. For more information, visit  http://www.dieselforum.org .

Connect with the Diesel Technology Forum
For the latest insights and information from the leaders in clean diesel technology, join us on Facebook, follow us on Twitter @DieselTechForum, or YouTube @DieselTechForum and connect with us on LinkedIn. Get it all by subscribing to our newsletter Diesel Direct for a weekly wrap-up of clean diesel news, policy analysis and more direct to your inbox.

Contact:
Sarah Dirndorfer
sdirndorfer@dieselforum.org
301.668.7230 (o) 301.706.8276 (c)




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Diesel Technology Forum via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum